Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females, 18 to 64 years of age, inclusive
DSM-IV diagnosis of schizophrenia
Patients currently on an optimal in-label dose of one of the following permitted antipsychotic treatments for at least 30 days: risperidone, olanzapine, or aripiprazole
Efficacy Clinical Global Impression of Severity (E-CGI-S) of 4 or 5 or
Not tolerating one of the permitted treatments and exhibits one of the allowable side-effects
You may not be if
Any other current Axis I disorder other than schizophrenia which is the focus of treatment;
Acutely psychotic or patient's symptom severity requires hospitalization
Patient with significant cardiovascular illness (myocardial infarction, cardiac arrhythmia)
Clareo Health | Switching to Iloperidone From Other Antipsychotics in Schizophrenia
